CytomX Therapeutics, Inc. (CTMX)
2.855
+0.16
(+6.13%)
USD |
NASDAQ |
Sep 16, 12:19
CytomX Therapeutics Price to Book Value : 2.060 for Sept. 16, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| September 15, 2026 | 1.940 |
| September 14, 2026 | 2.308 |
| September 11, 2026 | 2.373 |
| September 10, 2026 | 2.417 |
| September 09, 2026 | 2.554 |
| September 08, 2026 | 2.633 |
| September 04, 2026 | 2.676 |
| September 03, 2026 | 2.655 |
| September 02, 2026 | 2.684 |
| September 01, 2026 | 2.647 |
| August 31, 2026 | 2.424 |
| August 28, 2026 | 2.316 |
| August 27, 2026 | 2.467 |
| August 26, 2026 | 2.395 |
| August 25, 2026 | 2.431 |
| August 24, 2026 | 2.373 |
| August 21, 2026 | 2.366 |
| August 20, 2026 | 2.373 |
| August 19, 2026 | 2.575 |
| August 18, 2026 | 2.445 |
| August 17, 2026 | 2.489 |
| August 14, 2026 | 2.424 |
| August 13, 2026 | 2.417 |
| August 12, 2026 | 2.518 |
| August 11, 2026 | 2.489 |
| Date | Value |
|---|---|
| August 10, 2026 | 2.482 |
| August 07, 2026 | 2.496 |
| August 06, 2026 | 2.431 |
| August 05, 2026 | 2.417 |
| August 04, 2026 | 2.395 |
| August 03, 2026 | 2.287 |
| July 31, 2026 | 2.236 |
| July 30, 2026 | 2.366 |
| July 29, 2026 | 2.287 |
| July 28, 2026 | 2.323 |
| July 27, 2026 | 2.344 |
| July 24, 2026 | 2.337 |
| July 23, 2026 | 2.402 |
| July 22, 2026 | 2.402 |
| July 21, 2026 | 2.467 |
| July 20, 2026 | 2.539 |
| July 17, 2026 | 2.611 |
| July 16, 2026 | 2.644 |
| July 15, 2026 | 2.655 |
| July 14, 2026 | 2.640 |
| July 13, 2026 | 2.669 |
| July 10, 2026 | 2.712 |
| July 09, 2026 | 2.853 |
| July 08, 2026 | 2.763 |
| July 07, 2026 | 2.77 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Regeneron Pharmaceuticals, Inc. | 2.535 |
| ACADIA Pharmaceuticals, Inc. | 3.606 |
| Alnylam Pharmaceuticals, Inc. | 23.76 |
| Anika Therapeutics, Inc. | 2.042 |
| Savara, Inc. | 7.513 |
Price to Book Value Related Metrics
| PS Ratio | 28.52 |
| Price | 2.855 |
| Earnings Yield | -16.00% |
| Market Cap | 622.10M |